Exelixis Inc Lessee, Operating Lease, Liability, to be Paid, Year One
Exelixis Inc (EXEL) had Lessee, Operating Lease, Liability, to be Paid, Year One of $28.52 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-10
- 2026-01-02: Lessee, Operating Lease, Liability, to be Paid, Year One $28.52M.
- 2025-01-03: Lessee, Operating Lease, Liability, to be Paid, Year One $26.53M.
- 2023-12-29: Lessee, Operating Lease, Liability, to be Paid, Year One $26.34M.
- 2022-12-30: Lessee, Operating Lease, Liability, to be Paid, Year One $18.06M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2026-01-02 | $28.52M 10-K · filed 2026-02-10 |
| 2025-01-03 | $26.53M 10-K · filed 2025-02-11 |
| 2023-12-29 | $26.34M 10-K · filed 2024-02-06 |
| 2022-12-30 | $18.06M 10-K · filed 2023-02-07 |
| 2021-12-31 | $5.64M 10-K · filed 2022-02-18 |
| 2021-01-01 | $4.83M 10-K · filed 2021-02-11 |
| 2020-01-03 | $4.54M 10-K · filed 2020-02-25 |
| 2018-12-28 | $2.79M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |